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Background: Human MutY glycosylase homolog (hMYH), a component of the base excision repair pathway, is
responsible for the generation of apurinic/apyrimidinic sites. Rad9-Rad1-Hus1 (9-1-1) is a heterotrimeric protein
complex that plays a role in cell cycle checkpoint control and DNA repair. In humans, hMYH and 9-1-1 interact
through Hus1 and to a lesser degree with Rad1 in the presence of DNA damage. In Saccharomyces pombe, each
component of the 9-1-1 complex interacts directly with SpMYH. The glycosylase activity of hMYH is stimulated by
Hus1 and the 9-1-1 complex and enhanced by DNA damage treatment. Cells respond to different stress conditions
in different manners. Therefore, we investigated whether Rad9 interacted with hMYH under different stresses.
Here, we identified and visualized the interaction between hRad9 and hMYH and investigated the functional
consequences of this interaction.
Results: Co-IP and BiFC indicates that hMYH interacts with hRad9. As shown by GST-pull down assay, this
interaction is direct. Furthermore, BiFC with deletion mutants of hMYH showed that hRad9 interacts with N-terminal
region of hMYH. The interaction was enhanced by hydroxyurea (HU) treatment. mRNA and protein levels of hMYH
and hRad9 were increased following HU treatment. A marked increase in p-Chk1 (S345) and p-Cdk2 (T14, Y15) was
observed. But this phosphorylation decreased in siMYH- or siRad9-transfected cells, and more pronounced decrease
observed in co-transfected cells.
Conclusions: Our data reveal that hRad9 interacts directly with N-terminal region of hMYH. This interaction is
enhanced by HU treatment. Knockdown of one or both protein result in decreasing Chk1 and Cdk2
phosphorylation. Since both protein functions in the early detection of DNA damage, we suggest that this
interaction occurs early in DNA damage pathway.
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Protein-protein interactionBackground
A major product of DNA damage, 8-oxoguanine (8-oxoG),
is generated in DNA following oxidative damage by react-
ive oxygen species (ROS). If not repaired, this 8-oxoG re-
sults in a transversion from G:C to T:A [1]. The human
MutY glycosylase homolog (hMYH) is involved in base ex-
cision repair (BER); which is initiated by recognition and* Correspondence: yshan@konkuk.ac.kr
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unless otherwise stated.removal of adenine residues from DNA. hMYH cleaves
the N-glycosidic bond between a target base and its deoxy-
ribose sugar. This results in an apurinic/apyrimidinic (AP)
site [2]. hMYH has multiple forms that arise from multiple
transcription initiation sites and alternative splicing of
hMYH mRNA transcripts [3].
Rad9-Rad1-Hus1 forms a heterotrimeric protein com-
plex called 9-1-1. The structure of this complex is simi-
lar to that of proliferating cell nuclear antigen (PCNA), a
replication clamp [4]. Previous studies have shown that
Rad17 recruits the 9-1-1 complex to DNA damage sitesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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onto primed DNA [5]. The 9-1-1 complex has several
functions, such as DNA repair, cell cycle checkpoint con-
trol, BER, homologous recombination, mismatch repair,
apoptosis, and 3′–5′ exonuclease activity [6-9]. The com-
plex also interacts with and/or stimulates components of
the BER pathway, including polymerase β (Polβ), flap endo-
nuclease 1 (FEN1), replication protein A (RPA), and DNA
ligase 1 (Lig1) [10-13]. hRad9 is regulated by phosphoryl-
ation and by the differential interactions with different
protein partners, which likely determines the multiple
functions of hRad9 [6,14].
Protein-protein interactions can be studied by several
methods. Bimolecular fluorescence complementation
(BiFC) is based on the complementation of two non-
fluorescent fragments of a fluorophore. Interaction be-
tween proteins fused to the fragments facilitates the as-
sociation of the non-fluorescent fragments [15]. Dronpa
is a green fluorescent protein (GFP)-like protein that
photoswitches between a fluorescent “on” state and a
non-fluorescent “off” state in response to light irradi-
ation [15]. Previously, we had successfully generated a
Dronpa-BiFC system to visualize the interaction be-
tween hHus1-hMYH and an intercomplex interaction
between hRad1-hHus1 [16].
In Saccharomyces pombe, each component of the 9-1-
1 complex interacts directly with SpMYH, and these in-
teractions were increased after treatment with H2O2
[12]. Furthermore, human 8-oxoguanine DNA glycosy-
lase (hOGG1), another DNA glycosylase, can interact
with each subunit of the 9-1-1 complex. The interaction
between the 9-1-1 complex and hOGG1 increase hOGG1
enzyme activity [17]. However, according to previous re-
port by Shi et al., hMYH interacts with the 9-1-1 complex
through hHus1 and interacts to a lesser degree with
hRad1, but not with hRad9 [18]. The glycosylase activity
of hMYH is stimulated by hHus1 and the 9-1-1 complex,
and this interaction is enhanced by DNA damaging treat-
ments [18]. Therefore, it would be interesting to study the
different interactions between 9-1-1 and hMYH under
various conditions.
In this study, we have used a Dronpa-BiFC system and
shown for the first time that hRad9 interacts with the
N-terminal region of hMYH. We also examined the phy-
siological effects of the hRad9 and hMYH interaction
by exposing cells to damaging agents such as HU. The
mRNA levels of hMYH and hRad9 were increased after
treatment with HU, but not after treatment with H2O2.
Moreover, the interaction between hMYH and hRad9 was
also indicated by FRET (Fluorescence resonance energy
transfer), which increased after HU treatment. Cell cycle
arrest, induced by p-Chk1 (S345), is evident from the in-
crease in the inactive form of cyclin-dependent kinase 2
(Cdk2, phosphorylated at T14, Y15). Phosphorylation ofChk1 and Cdk2 decreased in hMYH and hRad9 knock-
down cells; this decrease was more pronounced after HU
treatment. hRad9 interacted with hMYH as a component
of the 9-1-1 complex because depletion of Hus1 reduced
the interaction. We hypothesize that this interaction oc-
curs during the early stages of DNA damage repair.
Results and discussion
hMYH physically interacts with hRad9
To determine whether hRad9 interacts with hMYH, co-
immunoprecipitation (co-IP) was performed using HEK293
cells transfected with c-myc and FLAG-tagged hRad9 or
c-myc-tagged hMYH and FLAG-tagged hRad9. After in-
cubation for 24 h, cell lysates were extracted and immu-
noprecipitated with an anti-c-myc antibody. Precipitated
samples were analyzed by immunoblotting with anti-
FLAG and anti-c-myc antibodies. FLAG-hRad9 was
precipitated through its interaction with c-myc-hMYH
(Figure 1A). In western blot analysis, hRad9 was visualized
as several bands due to differences in the phosphorylation
states. These results may indicate a physical interaction
between hMYH and hRad9. The endogenous interaction
between hRad9 and hMYH was confirmed by co-IP with
anti-hMYH antibody. hRad9 immunoprecipitated with
hMYH (Figure 1B), indicating that endogenous hMYH in-
teracts with hRad9.
To determine the involvement of the 9-1-1 complex in
the interaction between hMYH and hRad9, Hus1 expres-
sion was knocked down using specific siRNA. In Hus1-
depleted cells, the interaction between hMYH and hRad9
was decreased (Figure 1C). This result indicates that
hRad9 interacts with hMYH as part of the 9-1-1 complex.
Bacterially expressed and purified His-hRad9 and GST-
hMYH were used in GST pull-down assays to demonstrate
the physical interaction between hMYH and hRad9. GST
or GST-hMYH was immobilized on glutathione-Sepharose
beads and used to pull-down purified His-hRad9. We ob-
served a band for His-hRad9 in the pull-down assay with
GST-hMYH, but not with GST alone, indicative of a direct
interaction between hMYH and hRad9 (Figure 1D). Our
results differ from those obtained by Shi et al. [18], which
did not observe an interaction between hMYH and hRad9
in GST pull-down assays.
hRad9 interacts with the N-terminal region of hMYH
The N-terminal region of hMYH contains sites for RPA
binding (amino acids 1–32) and function in substrate spe-
cificity, and the C-terminal region is important for glycosy-
lase activity [19]. We created hMYH mutants with N-, C-, or
N- and C-terminal deletions [ΔN (amino acids 75–547),
ΔC (amino acids 1–487), and ΔNC (amino acids 75–487),
respectively] to determine the functional impact of the
hMYH and hRad9 interaction on substrate specificity and
glycosylase activity. We successfully used the Dronpa-BiFC
DC
BA
Figure 1 Interaction between hMYH and hRad9. (A) HEK293 cells were transfected with c-myc and FLAG-tagged hRad9, or c-myc-tagged
hMYH and FLAG-tagged-hRad9 as indicated. Co-IP was performed with anti-c-myc antibody, and the immunoprecipitates were immunoblotted
with anti-FLAG and anti-c-myc antibodies. (B) Lysates from untransfected HEK293 cells were used for the immunoprecipitation of hMYH with an
anti-hMYH antibody. Immunoblotting was performed using anti-hMYH and anti-hRad9 antibodies. Lane 1: input sample, lanes 2 and 3: proteins
immunoprecipitated with mouse IgG or anti-hMYH antibody. (C) HEK293 cells were transfected with siHus1 or siGFP. Total cell lysates were used
for co-IP with hRad9 antibody. (D) Pull-down of purified His-hRad9 with GST-hMYH bound to glutathione-Sepharose beads. Lane 1: purified
His-hRad9, lanes 2 and 3: pull-downs with GST and GST-hMYH, respectively.
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that interacts with hRad9 and to visualize the interaction
between hMYH-hHus1. The optimum fragments for
Dronpa cleavage were selected according to a structural
analysis of GFP and mRFP1. BiFC vectors for visua-
lization of the interaction between hRad9 and hMYH
were constructed as described in the Methods section
[16]. The Dronpa C-terminus was fused to hRad9, and the
Dronpa N-terminus was fused to either full-length hMYH
(pcDNA3-c-myc/hMYH-LDN) or hMYH deletion mutants
(pcDNA3-c-myc/hMYHΔN-LDN, pcDNA3-c-myc/hMYH-
ΔC-LDN, pcDNA3-c-myc/hMYH-ΔNC-LDN). The vector
used for the Dronpa-BiFC system is shown in Figure 2A.
The transient expression of transfected proteins in cells was
confirmed by immunoblotting (Figure 2B).
HEK293 cells were transfected with different vector sets of
plasmids (Dronpa-full, hMYH-LDN/DCL-hRad9, hMYH-
ΔN-LDN/DCL-hRad9, hMYH-ΔC-LDN/DCL-hRad9, andhMYH-ΔNC-LDN/DCL-hRad9). Cells were incubated for
24 h, and Dronpa fluorescence was visualized by fluores-
cence microscopy. Dronpa fluorescence was observed in
cells transfected with native Dronpa and in cells co-
transfected with hMYH-LDN/DCL-hRad9 and hMYH-
ΔC-LDN/DCL-hRad9, but no fluorescence was observed
in cells transfected with hMYH-ΔN-LDN/DCL-hRad9
and hMYH-ΔNC-LDN/DCL-hRad9 (Figure 2C). These
results showed that hRad9 interacts with the N-terminal
region of hMYH. The Dronpa fluorescence observed in
cells transfected with DCL-hRad9 and hMYH-LDN or
hMYH-ΔC-LDN was due to reconstitution of functional
Dronpa facilitated by the interaction between hRad9
and hMYH.
Photoswitching activity used to identify Dronpa pro-
tein [16]. To evaluate the photoswitching activity of na-
tive or complemented Dronpa fragments, HEK293 cells
were co-transfected with vectors expressing Dronpa or
Figure 2 hRad9 interacts with the N-terminal region of hMYH. (A) Vector for the Dronpa-BiFC system used to identify the interacting region
of hMYH. Expression vectors were created as previously described; however, the N-terminus of Dronpa (DN, 1–164) was C-terminally fused to
either full-length, wild-type hMYH or mutant hMYH [ΔN, ΔC, ΔNC]. The C-terminal region of Dronpa (DC, 165–224) was N-terminally fused to
hRad9. Dronpa and DCL-hRad9 were tagged with FLAG; hMYH-full-LDN and the deletion mutants were tagged with c-myc. (B) The expression of
each protein in transfected HEK293 cells was detected by immunoblotting with anti-FLAG and anti-c-myc antibodies. (C) The Dronpa-BiFC system
demonstrated that the N-terminal region of hMYH is important for the interaction between hMYH and hRad9. HEK293 cells were seeded on a
cover glass-bottom dish at a density of 1 × 105 cells per well. Cells were transfected with plasmids encoding full-length hMYH-LDN or a deletion
mutant (hMYH-ΔN-LDN, hMYH-ΔC-LDN, or hMYH-ΔNC-LDN) and DCL-Rad9, as indicated to the left of the figure and incubated for 24 h.
Fluorescence was assessed using a confocal fluorescence microscope with 488-nm excitation and 530-nm emission filters. Scale bar, 50 μm.
Agustina et al. BMC Molecular Biology 2014, 15:17 Page 4 of 10
http://www.biomedcentral.com/1471-2199/15/17hMYH-LDN and DCL-hRad9. The cells were incubated
for 24 h and analyzed by confocal fluorescence micros-
copy. After visualization, cells exhibiting Dronpa fluores-
cence were irradiated at 488 nm for 2 min to induce
photobleaching and then photoactivated at 430 nm for
30 s. The similar results were obtained with native and
complemented Dronpa fragments (data not shown).
To confirm this interaction, we transfected different
sets of vectors into HEK293 cells (c-myc, c-myc-hMYH-
full, c-myc-hMYH-ΔN, c-myc-hMYH-ΔC, or c-myc-
hMYH-ΔNC and FLAG-hRad9). After incubation for 24 h,
cell lysates were extracted and immunoprecipitated with
anti-c-myc antibody (Figure 3A). Immunoblot analysis was
performed with anti-c-myc or anti-FLAG antibody. In
agreement with Figure 2C, FLAG-hRad9 precipitated withc-myc-hMYH-full and c-myc-hMYH-ΔC (Figure 3A upper
panel). To further demonstrate the direct interaction be-
tween hRad9 and hMYH, we performed a GST pull-down
assay, as previously described. As same with IP results,
Purified His-hRad9 was pulled down by GST-hMYH-full
and GST-hMYH-ΔC, but not by GST alone, GST-hMYH-
ΔN, and GST-hMYH-ΔNC (Figure 3B). These results indi-
cate that the N-terminal region of hMYH facilitates the
interaction between hMYH and hRad9.
HU treatment increases the expression of hRad9 and
hMYH, leading to cell cycle arrest
We examined the physiological effects of the hRad9 and
hMYH interaction by exposing cells to damaging agents
(HU). hMYH and hRad9 mRNA levels were examined
AB
Figure 3 hMYH physically interacts with hRad9. (A) HEK293 cells were transfected with plasmids encoding c-myc, c-myc-hMYH-full, or a
c-myc-tagged hMYH deletion mutants (−ΔN, −ΔC, or -ΔNC) and FLAG-tagged hRad9, as indicated at the top of the figure. Co-IP was performed with
anti-c-myc antibody, and immunoprecipitates were immunoblotted with anti-FLAG and anti-c-myc antibodies. (B) hRad9 directly interacts with the
N-terminus of hMYH. A GST pull-down assay was performed using GST, GST-hMYH-full, or a GST-hMYH deletion mutants (ΔN, ΔC, or ΔNC). Purified
His-hRad9 was incubated with GST, GST-hMYH-full, or a GST-hMYH deletion mutants immobilized on glutathione beads. Bound proteins were
separated by SDS-PAGE and detected with immunoblotting using anti-GST and anti-His antibodies. Lane 1: purified His-hRad9, lanes 2–6: pull-downs of
His-hRad9 with GST (lane 2), GST-hMYH-full (lane 3), GST-hMYH-ΔN (lane 4), GST-hMYH-ΔC (lane 5), and GST-hMYH-ΔNC (lane 6).
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sity was higher in HU-treated samples (0.85), compared
to the intensity in untreated (0.55) and H2O2-treated
(0.60) samples. The same result was observed for hRad9,
which increased after HU treatment (0.72 vs. 0.40 in un-
treated and 0.43 in H2O2-treated). Thus, we noted a
marked increase in hRad9 and hMYH mRNA levels
after treatment with HU, but not after H2O2 treatment
(Figure 4A). Moreover, hMYH and hRad9 protein ex-
pression also increased in HU-treated cells, but not in
H2O2-treated cells.
HU arrests cell cycle progression by inhibiting ribonu-
cleotide diphosphate reductase. p-Chk1, an indicator of
DNA damage, was detected in both HU- and H2O2-
treated cells (Figure 4B). p-Chk1 induces cell cycle ar-
rest. Consistently, the phosphorylated, inactive form of
Cdk2 (p-Cdk2, T14, Y15), which does not promote cell
cycle progression, was higher in HU-treated cells.
To further study the functional impact of the inter-
action between hRad9 and hMYH in HU-treated cells,
we knockdown the expression of hMYH and/or hRad9
using siRNA. siGFP-transfected cells were used as a
control. After transfection, cells were treated with HU,
and protein expression was analyzed by immunoblot-
ting. In siGFP-transfected cells, p-Chk1 (S345) and p-
Cdk2 (T14, Y15) were detected, indicating that HU
treatment induced cell cycle arrest (Figure 4C). p-Chk1
and p-Cdk2 levels were lower in HU-treated cells trans-
fected with siRad9 and/or siMYH (Figure 4C). Thereduction in p-Cdk2 was more pronounced in cells in
which both hMYH and hRad9 were knocked down.
The interaction and co-localization of hMYH and hRad9 in
nuclear foci after exposure to genotoxic stress
The 9-1-1 complex and hMYH participate in DNA dam-
age repair [2,4]. The interaction between hRad9 and
hMYH after HU treatment was examined by FRET ana-
lysis. HEK293 cells were transfected with ECFP/hMYH
and EYFP/hRad9, individually or together. Using con-
focal fluorescence microscopy, we detected ECFP and
EYFP fluorescence in all transfected cells. FRET fluores-
cence was only observed in cells co-transfected with
ECFP/hMYH and EYFP/hRad9. Moreover, higher inten-
sity FRET fluorescence was seen in cells treated with
HU, suggesting that HU treatment enhances the inter-
action between hRad9 and hMYH (Figure 5A).
The interaction between hRad9 and hMYH exhibited a
relatively high FRET intensity (Figure 5B). Given this re-
sult, we determined whether endogenous hMYH and
hRad9 localized to the same nuclear foci after HU
treatment. In immunofluorescence analysis, hMYH and
hRad9 staining in the nucleus of untreated cells was
faint (Figure 5C). However, in HU-treated cells, hMYH
and hRad9 formed discrete nuclear foci, and a signifi-
cant fraction of the hMYH nuclear foci co-localized
with hRad9, indicating that hMYH and the 9-1-1 com-




Figure 4 HU induces hMYH and hRad9 expression. (A) Reverse transcription-polymerase chain reaction (RT-PCR) analysis of hMYH and hRad9
mRNA expression. Total RNA was extracted from untreated or treated (HU or H2O2) cells and used for RT-PCR. The levels of hMYH and hRad9
mRNA were determined and normalized to β-actin levels (unpaired t-test; p < 0.05; *significant; **not significant) (B) hRad9 and hMYH expression
in HEK293 cells increased after HU treatment, leading to cell cycle arrest at the G1/S phase. Total cell lysates from untreated, HU-treated, or
H2O2-treated cells were used for immunoblotting to measure the expression of hMYH, hRad9, ATR, p-Chk1 (S345), Chk1, p-Cdk2 (T14, Y15),
and Cdk2 proteins. (C) hRad9 and hMYH knockdown reduced the phosphorylation of Chk1 and Cdk2 in HU-treated cells. HEK293 cells were
transfected with siRNA for GFP, hMYH, hRad9, or hMYH and hRad9 as indicated in the figure. Transfected cells were treated with 20 mM HU for
1 h, and then allowed to recover in fresh medium for 2 h. Total cell lysates were used for immunoblotting analysis with anti-hMYH, anti-hRad9,
anti-ATR, anti-p-Chk1 (S345), anti-Chk1, anti-p-Cdk2 (T14, Y15), anti-Cdk2, and anti-actin antibodies.
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In this study, we showed that hRad9 interacts with hMYH
by co-IP of over-expressed c-myc-hMYH and FLAG-hRad9
(Figure 1A) and co-IP of endogenous hMYH and hRad9
(Figure 1B). We confirmed the interaction in GST pull-
down assays using GST-hMYH and His-hRad9 (Figure 1D).
Moreover, we observed that interaction between hMYHand hRad9 was independent with DNA (Additional file 1).
The results showed that the proteins interact directly. We
also observed that hMYH interacts with hHus1 [16], and
hRad1 (data not shown). In addition, the Dronpa-BiFC sys-
tem, used previously to visualize the intercomplex interac-
tions between hHus1 and hRad1 and between hMYH and
hHus1 [16], was used to show that hRad9 interacts with
CA B
Figure 5 DNA damage (HU) promotes the interaction between hRad9 and hMYH. (A) Fluorescence resonance energy transfer (FRET) was
used to analyze the interaction between over-expressed hRad9 and hMYH after DNA damage. Cells transfected with ECFP and EYFP or ECFP/
hMYH and EYFP/hRad9 were treated with or without HU. ECFP, EYFP, and FRET fluorescence was observed with a fluorescence microscope at
440/480 nm (ECFP), 480/535 nm (EYFP), and 440/535 nm (FRET). Scale bar, 50 μm. (B) FRET efficiency was used to quantify the interaction
between hMYH and hRad9 after DNA damage. HEK293 cells were transfected with ECFP and EYFP or ECFP/hRad9 and EYFP/hMYH as indicated to
the left of the figure. Cells were treated with or without HU. ECFP, EYFP, and FRET fluorescence were measured at the indicated wavelengths.
FRET efficiency was quantified in five control cells and five HU-treated cells. Standard error is shown. Scale bar, 10 μm. (C) Immunofluorescence of
endogenous hMYH and hRad9. Cells were treated with or without 20 mM HU for 1 h and allowed to recover for 2 h. Cells were stained with
antibodies against hMYH (FPG 456, green), hRad9 (FPR 552, yellow), and To-pro®-3 (nuclei, red). Scale bar, 10 μm.
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ous study by Shi et al., in which hMYH was not detected in
GST pull-down assays using GST-hRad9 [18]. Shi et al. in-
vestigated whether GST-hHus1, GST-hRad1, and GST-
hRad9 pulled down His-hMYH. Their results showed that
His-hMYH interacted directly with hHus1 and hRad1, but
not with hRad9. They also found that GST-SpMYH pulled
down the 9-1-1 complex. We suggest that the differences
between their results and ours may be due to the different
protein constructs used or the weak binding of hRad9 to
hMYH [18,20,21].
In our lab, we found that disruption of hMYH and the
9-1-1 complex sensitizes cells to hydroxyurea (HU) and
ultraviolet (UV) irradiation [22]. It is already known that
9-1-1 complex function in the early detection of DNA
damage and assists other protein to bind to the site of
damage [6-9]. On the other hand, hMYH function in
creating AP-site in the early BER pathway [2]. Moreover,
knockdown of hMYH and hRad9 induced the decreaseof phosphorylation in the Chk1 and Cdk2, an upstream
in the DNA damage repair pathway (Figure 4C). There-
fore, we suggest that the interaction between hMYH and
9-1-1 occurs early in the DNA damage response and
functions as an adaptor for other proteins at lesion sites
to activate checkpoint control.
The hRad9 and hMYH interaction was studied by fluor-
escence resonance energy transfer (FRET). FRET occurs
upon energy transfer from a donor molecule (ECFP) to an
acceptor molecule (EYFP) [23]. Cells that over-expressed
ECFP/hMYH and EYFP/hRad9 were treated with HU.
FRET increased significantly in cells treated with HU
(Figure 5A).
We also analyzed the interacting region of hMYH
using the Dronpa-BiFC system. hMYH is significantly
larger than the bacterial protein and comprises the en-
tire MutY sequence plus extended N- and C-terminal
flanking domains [24]. These 50–60 amino acids ter-
minal domains are involved in subcellular targeting and
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motifs, for example, map to the N- and C-terminus, re-
spectively. These interactions suggest coupling of hMYH
to the DNA replication machinery [2,24]. The Dronpa-
BiFC system showed that hRad9 interacts with the N-
terminal region of hMYH (Figure 2C). Subsequently,
co-IP and GST pull-down assays showed that hRad9
interacts directly with the N-terminal region of hMYH
(Figure 3A,B).
hMYH and hRad9 mRNA and protein levels in-
creased after HU treatment, but not after H2O2
treatment (Figure 4A,B). HU inhibits ribonucleotide
diphosphate reductase, thereby blocking DNA synthesis
and repair [25]. When DNA is damaged, cell cycle pro-
gression arrests or slows to allow time for DNA repair
[26]. The cell cycle checkpoint proteins Rad9-Rad1-Hus1
complex play important roles in both cell cycle checkpoint
control and DNA repair [26]. Deletion of each gene en-
coding the three proteins in the fission yeast S. pombe in-
activates S/M, intra-S, and G2/M checkpoint controls.
Endogenous hMYH in HEK293 cells increased during S
phase and decreased in M phase [22]. However, a basal
level of hMYH was maintained during M phase. Disrup-
tion of hMYH levels reduced the amount of Chk1 acti-
vated by HU. These results indicate that, although mainly
induced from late G1 to S phase, Chk1 activation can also
be induced by DNA damage during G2/M phase and at-
tenuated by hMYH disruption [22].
Chk1 on chromatin undergoes ATR-dependent phos-
phorylation in response to DNA damage. Phosphoryl-
ation appears to disrupt intramolecular interactions,
leading to an open conformation of Chk1 and to check-
point activation [27]. CDKs (Cyclin-dependent kinases)
are heterodimeric serine/threonine protein kinases that
control cell cycle progression. Among them, the Cdk1-
cyclin B complex controls cell cycle progression in G2/
M phase, and Cdk2-cyclin E/A complexes function in
the G1/S and S/G2 transitions [28]. Cell cycle entry into
mitosis is regulated by Cdk1 activation, which is con-
trolled by cyclin binding and phosphorylation at T161.
On the other hand, Cdk2 is activated during the pro-
gression of mitosis by dephosphorylation at T14 and
Y15. Thus, phosphorylation of Cdk2 (T14, Y15) is indi-
cative of cell cycle arrest [29].
In cells depleted of hMYH and hRad9 by siRNA knock-
down, p-Chk1 and p-Cdk2 expression levels decreased
(Figure 4C). The decrease in p-Chk1 in single and double
knockdowns indicates that hMYH and hRad9 are defective
in promoting ATR activity. Therefore, we can conclude
that hMYH and hRad9 interaction are important for the
DNA damage response.
We suggest that hMYH and hRad9 interact early in
the process of cell cycle arrest. Further studies to eluci-
date the mechanism that regulates interactions betweenhMYH and the 9-1-1 complex in response to different
types of DNA damage are required.
Methods
Cell line and treatments
Human embryonic kidney (HEK293) cells were grown in
Dulbecco’s modified Eagle’s Medium (DMEM; Welgene,
Daegu, Korea) containing 10% fetal bovine serum (FBS; JR
Scientific, Woodland, CA) and 1% penicillin-streptomycin
solution (Welgene) at 37°C in a 5% CO2 incubator. Cells
were seeded at 1 × 105cells/ml then incubated overnight
before transfection or treatment with damage reagent
(20 mM HU for 1 h or 5 mM H2O2 for 40 min).
Transient expression in HEK293 cells
Cells were transiently transfected using Lipofectamine™
2000 reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol and incubated 24 h. Cells were
lysed in lysis buffer [50 mM Tris–HCl (pH 8.0), 100 mM
NaCl, 5 mM EDTA, 1% Nonidet P-40, 10 g/ml PMSF, and
protease inhibitor cocktail (Sigma, St. Louis, MO)] for
40 min at 4°C. Lysed cells were centrifuged for 20 min,
and supernatants were collected for western blotting.
Immunoprecipitation
Total cell lysates were incubated with anti-c-myc (Santa
Cruz Biotechnology, CA, USA) or anti-FLAG antibody
(Sigma) for 2 h and then with A/G PLUS-Agarose beads
(Santa Cruz Biotechnology) overnight. Protein-bead com-
plexes were precipitated by centrifugation, washed with
phosphate-buffered saline (PBS; Sigma), and mixed with
2× SDS-PAGE loading buffer. The samples were then se-
parated by SDS-PAGE and analyzed by immunoblotting.
Endogenous proteins were co-immunoprecipitated using
hMYH antibody (Abnova, Taipei, Taiwan) and the Immu-
noCruz™ IP/WB Optima B System (Santa Cruz Biotechnol-
ogy) according to the manufacturer’s protocol. Immunoblot
analysis was conducted using mouse anti-MYH, anti-Rad9
(Novus Biologicals, Littleton, CO), and anti-Hus1 (Santa
Cruz Biotechnology) antibodies.
GST pull-down assay
A GST gene fusion system (Amersham Biosciences,
Uppsala, Sweden) was used to generate GST-tagged
hMYH wild type and mutants (ΔN, ΔC, and ΔNC). For
GST pull-down assays, fusion proteins were adsorbed to
glutathione-Sepharose 4B beads. His-purified hRad9
protein was then incubated with GST or GST fusion
protein in binding buffer [50 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 0.3 mM DTT, 0.1% NP-40,
and protease inhibitor cocktail], and proteins were incu-
bated for 3 h at 4°C. The beads were washed, and bound
proteins were separated by SDS-PAGE analysis and
assessed by immunoblotting.
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Proteins were fractionated by an 8% or 10% SDS-PAGE
and transferred to a polyvinylidene fluoride (PVDF) mem-
brane (PALL Corporation, New York, NY). Membranes
were blocked with 3% skim milk and washed with TBS-
Tween 20. Membranes were then incubated with anti-
bodies against hMYH, hRad9, hHus1, c-myc, FLAG, and
ATR; p-Chk1 (S345); Chk1; p-Cdk2 (T14, Y15); Cdk2
(Santa Cruz Biotechnology) then incubated with appro-
priate horseradish peroxidase-conjugated secondary anti-
bodies (Santa Cruz Biotechnology). Protein bands were
detected using ECL Pico western blotting detection re-
agents (Pierce, Rockford, IL).
The Dronpa-BiFC system
The intact Dronpa molecule and non-fluorescent frag-
ments were fused to hMYH or hRad9 and inserted into the
pcDNA3-c-myc vector. The construction of a Dronpa N-
terminal and C-terminal fragment fused to a flexible linker
as described by Lee et al. [16]. Gene fragments correspond-
ing to the coding regions of hMYH and hRad9 (accession
numbers: hMYH, NM_012222; hRad9, NM_004584) were
amplified by PCR using a HotStarTaq kit (Qiagen, Venlo,
Netherlands).
hMYH full-length (amino acids 1–547), ΔN (amino acids
75–547), ΔC (amino acids 1–487), and ΔNC (amino acids
75–487) constructs
Specific primers were used to amplify the hMYH ΔN,
ΔC, and ΔNC regions of the hMYH gene. The PCR
products were cleaved and ligated into HindIII-XhoI-
digested pCMV-tag3A-c-myc or pGEX-4 T1 (GE
Healthcare, Princeton, NJ) vectors. All constructs were
confirmed by restriction enzyme mapping and DNA se-
quence analysis.
ECFP/hMYH-full, −ΔN, −ΔC, and -ΔNC and EYFP/hRad9
Gene fragments corresponding to the complete coding
region of hMYH-full, −ΔN, −ΔC, −ΔNC, and the
complete coding region of hRad9 were amplified by PCR
and subcloned into HindIII-XbaI-digested ECFP vector
and EcoR1-HindIII-digested EYFP vector (Clontech,
Mountain View, CA).
Dronpa fluorescence analysis
HEK293 cells were seeded on a cover glass-bottom dish
(SPL, Pocheon, South Korea), and co-transfected with
the indicated vectors. Cells were fixed with 4% parafor-
maldehyde. After washes with PBS, Dronpa fluorescence
was visualized under a confocal fluorescence microscope
(Olympus FV-1000; software, Olympus FluoView; Olympus,
Center Valley, PA) using 488-nm excitation and 530-nm
emission filters. After visualization of Dronpa fluorescence,
the cells were irradiated with a 488-nm laser for 2 minto induce photobleaching, followed by irradiation with a
430-nm excitation laser for 30 s. Photoswitching activity
was monitored for several cycles.
siRNA transfection
The siRNA sequences 5′-GGGCACAAGCUGGAGUA
CAACUACA-3′ (Santa Cruz Biotechnology) and 5′-
CACACAGUUGGAUAAACAU-3′ (Bioneer, Daejeon,
Korea) were used to target GFP and Hus1, respectively.
HEK293 cells were transfected with each siRNA and in-
cubated for 24 h. GFP was used as a negative control.
Reverse transcription-PCR (RT-PCR)
HEK293 cells were treated with H2O2 or HU as de-
scribed previously. RNA was extracted using a RiboEx
total RNA isolation kit (GeneAll Biotechnology, Seoul,
Korea) according to the manufacturer’s protocol. RNA
was reverse-transcribed for RT-PCR using Omniscript
reverse transcriptase (Qiagen) by following the manufac-
turer’s instructions. RT-PCR was carried out for 1.5 h at
37°C with primers specific for hMYH and. β-actin was
used as a control. DNA was amplified for 30 cycles, and
analyzed by agarose gel electrophoresis.
Fluorescence resonance energy transfer (FRET)
Cells (0.7 × 105) were seeded on cover glass-bottom
dish and incubated overnight. Cells were transfected
with ECFP/EYFP, ECFP/hMYH, or EYFP/hRad9 or co-
transfected with ECFP-EYFP or ECFP/hMYH-EYFP/
hRad9. After 24 h of incubation, cells were treated with
HU or untreated as previously described. Cells were fixed
with 4% paraformaldehyde. After incubation, cells were
washed with PBS. FRET fluorescence were observed with
a confocal fluorescence microscope (Olympus FV-1000;
software, Olympus FluoView Ver. 2.0c).
Immunofluorescence
Cells were grown on a cover glass-bottom dish (1 × 105)
and then treated with HU as previously described. Im-
munofluorescence was performed as described by Shi
et al. [18]. Cells were blocked with 15% FBS then reacted
with hMYH antibody or hRad9 antibody. Cells were
washed and incubated with anti-mouse FPG 456 (BioActs,
Incheon, Korea) or anti-rabbit FPR 552 (BioActs) anti-
body. The cells were washed with PBS, and nuclear DNA
was counterstained with To-pro®-3 (Invitrogen). Images
were captured with a confocal fluorescence microscope
(Olympus FV-1000).
Additional file
Additional file 1: hMYH interacts with hRad9 in DNA-independent
manner. HEK293 cell were treated or untreated Dnase for 20 min, in
37°C. Cells were lyased and conducted IP essay using anti-hRad9 antibody.
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